Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, 34734, Istanbul, Turkey.
Lab for Innovative Drugs (Lab4IND), Computational Drug Design Center (HİTMER), Bahçeşehir University, 34734, İstanbul, Türkiye.
Chembiochem. 2024 Jun 17;25(12):e202400008. doi: 10.1002/cbic.202400008. Epub 2024 May 29.
The RAS-MAPK signaling pathway, crucial for cell proliferation and differentiation, involves key proteins KRAS and SOS1. Mutations in the KRAS and SOS1 genes are implicated in various cancer types, including pancreatic, lung, and juvenile myelomonocytic leukemia. There is considerable interest in identifying inhibitors targeting KRAS and SOS1 to explore potential therapeutic strategies for cancer treatment. In this study, advanced in silico techniques were employed to screen small molecule libraries at this interface, leading to the identification of promising lead compounds as potential SOS1 inhibitors. Comparative analysis of the average binding free energies of these predicted potent compounds with known SOS1 small molecule inhibitors revealed that the identified compounds display similar or even superior predicted binding affinities compared to the known inhibitors. These findings offer valuable insights into the potential of these compounds as candidates for further development as effective anti-cancer agents.
RAS-MAPK 信号通路对细胞增殖和分化至关重要,涉及关键蛋白 KRAS 和 SOS1。KRAS 和 SOS1 基因的突变与多种癌症类型有关,包括胰腺癌、肺癌和青少年骨髓单核细胞白血病。人们非常关注鉴定针对 KRAS 和 SOS1 的抑制剂,以探索癌症治疗的潜在治疗策略。在这项研究中,采用了先进的计算技术来筛选该界面的小分子文库,从而确定了有前途的先导化合物作为潜在的 SOS1 抑制剂。对这些预测的有效化合物与已知的 SOS1 小分子抑制剂的平均结合自由能进行比较分析表明,与已知抑制剂相比,鉴定出的化合物表现出相似甚至更高的预测结合亲和力。这些发现为这些化合物作为有效的抗癌药物进一步开发的候选物提供了有价值的见解。